EP3206708A4 - Methods and compositions for the treatment of radiation-related disorders - Google Patents

Methods and compositions for the treatment of radiation-related disorders Download PDF

Info

Publication number
EP3206708A4
EP3206708A4 EP15875865.6A EP15875865A EP3206708A4 EP 3206708 A4 EP3206708 A4 EP 3206708A4 EP 15875865 A EP15875865 A EP 15875865A EP 3206708 A4 EP3206708 A4 EP 3206708A4
Authority
EP
European Patent Office
Prior art keywords
radiation
compositions
treatment
methods
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15875865.6A
Other languages
German (de)
French (fr)
Other versions
EP3206708A2 (en
EP3206708B1 (en
Inventor
Vadim Krivokrysenko
Elena Feinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statera Biopharma Inc
Original Assignee
Cleveland Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Biolabs Inc filed Critical Cleveland Biolabs Inc
Publication of EP3206708A2 publication Critical patent/EP3206708A2/en
Publication of EP3206708A4 publication Critical patent/EP3206708A4/en
Application granted granted Critical
Publication of EP3206708B1 publication Critical patent/EP3206708B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15875865.6A 2014-10-16 2015-10-16 Methods and compositions for the treatment of radiation-related disorders Active EP3206708B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064872P 2014-10-16 2014-10-16
US201562214572P 2015-09-04 2015-09-04
PCT/US2015/055986 WO2016109002A2 (en) 2014-10-16 2015-10-16 Methods and compositions for the treatment of radiation-related disorders

Publications (3)

Publication Number Publication Date
EP3206708A2 EP3206708A2 (en) 2017-08-23
EP3206708A4 true EP3206708A4 (en) 2018-05-30
EP3206708B1 EP3206708B1 (en) 2022-11-02

Family

ID=56285136

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15875865.6A Active EP3206708B1 (en) 2014-10-16 2015-10-16 Methods and compositions for the treatment of radiation-related disorders

Country Status (4)

Country Link
US (3) US10183056B2 (en)
EP (1) EP3206708B1 (en)
IL (1) IL251736B (en)
WO (1) WO2016109002A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183056B2 (en) * 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
US10702534B2 (en) 2017-03-31 2020-07-07 AI Therapeutics, Inc. Compositions and methods relating to the radioprotective effects of apilimod
PL3716967T3 (en) 2017-11-30 2023-12-11 Enzychem Lifesciences Corporation Compositions for prevention or treatment of acute radiation syndrome
US20210236594A1 (en) * 2018-04-24 2021-08-05 Genome Protection, Inc. Methods for improving frailty and aging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151994A1 (en) * 2012-04-02 2013-10-10 Health Research, Inc. Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
WO2014098649A1 (en) * 2012-12-18 2014-06-26 Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" Compositions and methods using toll-like receptor 5 and toll-like receptor agonist

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
EP0503012B1 (en) 1990-09-28 1996-06-26 Sulzer Innotec Ag Hollow needle for medical use, and process for the manufacture of such needles
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69333110T2 (en) 1992-03-02 2004-05-06 Chiron S.P.A. WITH THE CYTOTOXIN OF HELICOBACTER PYLORI ASSOCIATED, IMMUNODOMINANT ANTIGEN USED IN VACCINE AND FOR DIAGNOSIS
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
AU2001234721B8 (en) 2000-01-31 2006-07-27 Munin Corporation Human Cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2002216500A1 (en) 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
DE60141773D1 (en) 2001-04-20 2010-05-20 Inst Systems Biology GREAT SIMILAR RECEPTOR 5-LIGANDS AND USE PROCESS
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
AU2004296828B2 (en) 2003-12-02 2011-07-07 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
US8580321B2 (en) 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006039701A1 (en) 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
AU2005325715B2 (en) 2004-12-16 2011-10-06 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP1838340B1 (en) 2004-12-22 2018-04-04 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US20070269406A1 (en) 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
KR20100034010A (en) 2007-06-15 2010-03-31 임뮤룩스, 인코포레이티드 Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
RU2010107199A (en) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) CONJUGATE POLYPEPTIDE-NUCLEIC ACID FOR IMMUNOPROPHYLAXIS OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2320948B1 (en) 2008-08-01 2013-03-06 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
CA2739454C (en) 2008-10-03 2018-05-01 Emory University Methods for the treatment of graft-versus-host disease
CN102482233A (en) 2009-05-21 2012-05-30 阿斯利康(瑞典)有限公司 Novel pyrimidine derivatives and their use in the treatment of cancer and other diseases
ES2443952T3 (en) 2009-09-02 2014-02-21 Novartis Ag Immunogenic compositions that include modulators of TLR activity
AP2012006253A0 (en) 2009-10-06 2012-06-30 Panacela Labs Inc Use of toll-like receptors and agonist for treating cancer.
DK2968346T3 (en) 2013-03-15 2024-05-06 Cancer Research Tech Llc Methods and compositions for modulating the gamma-glutamyl cycle
US10183056B2 (en) * 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151994A1 (en) * 2012-04-02 2013-10-10 Health Research, Inc. Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
WO2014098649A1 (en) * 2012-12-18 2014-06-26 Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" Compositions and methods using toll-like receptor 5 and toll-like receptor agonist

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BURDELYA L G ET AL: "Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: Implications for head-and-neck cancer radiotherapy", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 20120501 ELSEVIER INC. USA, vol. 83, no. 1, 1 May 2012 (2012-05-01), pages 228 - 234, XP009504811, DOI: 10.1016/J.IJROBP.2011.05.055 *
CHOW C PAUL ET AL: "Developmental toxicity study of CBLB502 in Wistar rats", REPRODUCTIVE TOXICOLOGY, vol. 46, 3 March 2014 (2014-03-03), pages 12 - 19, XP028853998, ISSN: 0890-6238, DOI: 10.1016/J.REPROTOX.2014.02.007 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2012, WANG ZHI-DONG ET AL: "Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis.", XP002780134, Database accession no. NLM23167416 *
KRIVOKRYSENKO VADIM I ET AL: "Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 343, no. 2, November 2012 (2012-11-01), pages 497 - 508, XP009504814, ISSN: 0022-3565 *
L. G. BURDELYA ET AL: "An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models", SCIENCE, vol. 320, no. 5873, 11 April 2008 (2008-04-11), pages 226 - 230, XP055014939, ISSN: 0036-8075, DOI: 10.1126/science.1154986 *
L. G. BURDELYA ET AL: "Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 20, 29 April 2013 (2013-04-29), pages E1857 - E1866, XP055221656, ISSN: 0027-8424, DOI: 10.1073/pnas.1222805110 *
LEI W ET AL: "Radioprotection activity of toll-like receptor 5 agonist CBLB502 protein", JOURNAL OF INTERNATIONAL PHARMACEUTICAL RESEARCH 20120626, vol. 39, no. 3, 2012, pages 225 - 231, XP009504816, ISSN: 1674-0440 *
LI WEIGUANG ET AL: "CBLB502, an agonist of Toll-like receptor 5, has antioxidant and scavenging free radicals activitiesin vitro", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 82, 22 October 2015 (2015-10-22), pages 97 - 103, XP029357939, ISSN: 0141-8130, DOI: 10.1016/J.IJBIOMAC.2015.10.033 *
See also references of WO2016109002A2 *

Also Published As

Publication number Publication date
US20210275627A1 (en) 2021-09-09
US20190142896A1 (en) 2019-05-16
EP3206708A2 (en) 2017-08-23
IL251736A0 (en) 2017-06-29
US20170239326A1 (en) 2017-08-24
US10857200B2 (en) 2020-12-08
WO2016109002A2 (en) 2016-07-07
IL251736B (en) 2019-11-28
US10183056B2 (en) 2019-01-22
WO2016109002A3 (en) 2016-09-01
EP3206708B1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
EP3185876A4 (en) Compositions and methods for treatment of neurological disorders
EP3212226A4 (en) Compositions and methods of use for treating metabolic disorders
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3174894A4 (en) Compositions and methods of use for treating metabolic disorders
EP3240510A4 (en) Glaucoma treatment devices and methods
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3220906A4 (en) Compositions and methods for treating lysosomal disorders
EP3104706A4 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
EP3189036A4 (en) Compositions and methods for treating proliferation disorders
EP3182977A4 (en) Compositions and methods to treat vision disorders
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3134120A4 (en) Compositions and methods for treating cytokine-related disorders
EP3224362A4 (en) Therapeutic compositions comprising transcription factors and methods of making and using the same
EP3201225A4 (en) Methods and compositions for treatment of conditions associated with elevated triglycerides
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
EP3142699A4 (en) Compositions and methods for treating metabolic disorders
EP3185872A4 (en) Formulations of testosterone and methods of treatment therewith
EP3240577A4 (en) Methods and compositions for treating brain diseases
EP3229813A4 (en) Treatment of hmgb1-mediated inflammation
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
EP3134108A4 (en) Agents and methods of treatment
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3185910A4 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170504

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180503

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/112 20060101ALI20180420BHEP

Ipc: A61P 39/00 20060101ALI20180420BHEP

Ipc: A61K 38/16 20060101AFI20180420BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191218

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220527

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FEINSTEIN, ELENA

Inventor name: KRIVOKRYSENKO, VADIM

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1528265

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015081475

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20221102

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1528265

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230302

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230202

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230302

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015081475

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20230803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015081475

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20231031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231016

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231016

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240501

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221102